NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.14
+3.24%Margins
Gross margin
-165.5%
EBITDA margin
-869.6%
EBIT margin
-982.4%
Net margin
-928.4%
FCF margin
-828.3%
-84.8%
Return on equity
-63.7%
Return on assets
-78.4%
Return on invested capital
0.06x
Asset turnover
-$293.7M
Cash from operations
$4.27
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of May 1, 2026